Coffee consumption is linked to a longer lifespan and a lower risk of cardiovascular disease

According to a study published today in the European Journal of Preventive Cardiology, a review of the ETUC. The results applied to ground, instant and decaffeinated varieties.

In this large observational study, ground, instant, and decaffeinated coffee were associated with equivalent reductions in the incidence of cardiovascular disease and death from cardiovascular disease or any other cause. The results suggest that light to moderate consumption of ground, instant and decaffeinated coffee should be considered part of a healthy lifestyle.”

Professor Peter Kistler, study author, Baker Heart and Diabetes Research Institute, Melbourne, Australia

There is little information on the impact of different coffee preparations on heart health and survival. This study examined associations between coffee types and incident arrhythmias, cardiovascular disease and death using data from the UK Biobank, which recruited adults aged 40-69. Cardiovascular diseases included coronary heart disease, congestive heart failure and ischemic stroke.

The study included 449,563 participants who were free of arrhythmias or other cardiovascular disease at baseline. The median age was 58 years and 55.3% were female. Participants completed a questionnaire asking how many cups of coffee they drank each day and whether they usually drank instant, ground (like cappuccino or filtered coffee) or decaffeinated coffee. They were then grouped into six daily intake categories, consisting of none, less than one, one, two to three, four to five, and more than five cups per day. The usual type of coffee was instant in 198,062 (44.1%) participants, ground in 82,575 (18.4%), and decaffeinated in 68,416 (15.2%). There were 100,510 (22.4%) non-coffee drinkers who served as the comparison group.

Coffee drinkers were compared to nondrinkers for the incidence of arrhythmias, cardiovascular disease, and death, after adjusting for age, sex, ethnicity, obesity, high blood pressure, diabetes, obstructive sleep apnea, smoking, and drinking tea and alcohol. Outcome information was obtained from medical records and death certificates. The median follow-up was 12.5 years.

A total of 27,809 (6.2%) participants died during follow-up. All types of coffee have been associated with reduced deaths from any cause. The greatest risk reduction observed with two to three cups a day, which compared to no coffee consumption, was associated with a 14%, 27% and 11% lower probability of death for decaffeinated, ground preparations and instantaneous, respectively.

Cardiovascular disease was diagnosed in 43,173 (9.6%) participants during follow-up. All coffee subtypes were associated with a reduction in incident cardiovascular disease. Again, the lowest risk was seen with two to three cups a day, which compared to abstinence from coffee was associated with a 6%, 20%, and 9% reduced likelihood of cardiovascular disease for decaffeinated, ground and instant coffee, respectively.

Arrhythmia was diagnosed in 30,100 (6.7%) participants during follow-up. Ground and instant coffee, but not decaffeinated, was associated with a reduction in arrhythmias, including atrial fibrillation. Compared to non-drinkers, the lowest risks were observed with four to five cups per day for ground coffee and two to three cups per day for instant coffee, with 17% and 12% reduced risk respectively.

Professor Kistler said: “Caffeine is the best-known constituent of coffee, but the drink contains more than 100 biologically active components. It is likely that non-caffeinated compounds are responsible for the observed positive relationships between coffee consumption, cardiovascular disease and Our findings indicate that drinking small amounts of coffee of all types should not be discouraged, but can be enjoyed as a heart-healthy behavior.

Source:

European Society of Cardiology (ESC)

Journal reference:

Cheng, D. et al. (2022) The impact of coffee subtypes on incident cardiovascular disease, arrhythmias and mortality: long-term results from the UK Biobank. European Journal of Preventive Cardiology. doi.org/10.1093/eurjpc/zwac189.

Leave a Reply